HI
SAGE

HBK Investments’s Sage Therapeutics SAGE Stock Holding History

HBK Investments’s Portfolio SAGE Stock Details SAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-9,600
Closed -$1.36M – 1381
2018
Q3 		$1.36M Buy
+9,600
New +$1.48M 0.01% 636
2018
Q1 		– Sell
-17,000
Closed -$2.8M – 1122
2017
Q4 		$2.8M Buy
+17,000
New +$1.65M 0.02% 371
2015
Q4 		– Sell
-7,600
Closed -$322K – 1095
2015
Q3 		$322K Sell
7,600
-18,381
-71% -$1.13M ﹤0.01% 838
2015
Q2 		$1.9M Buy
+25,981
New +$1.67M 0.02% 425

Other funds holding SAGE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

HBK Investments's SAGE Position: Q4 2018 in Review

HBK Investments sold out of Sage Therapeutics (SAGE) in Q4 2018, closing a stake of 9,600 shares — an estimated $1.36M sold.

HBK Investments first reported a position in SAGE in Q2 2015 and held it in 4 quarters. The position peaked at $2.8M in Q4 2017. 248 funds tracked by Wall St. Rank hold SAGE as of Q4 2018.

  • HBK Investments reported no remaining Sage Therapeutics position as of Q4 2018 after selling out during the quarter.
  • HBK Investments sold 9,600 Sage Therapeutics shares in Q4 2018, an estimated $1.36M.
  • HBK Investments first reported a position in Sage Therapeutics in Q2 2015 and held it in 4 quarters.
  • HBK Investments's Sage Therapeutics position peaked at $2.8M in Q4 2017.
  • 248 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2018.

Based on HBK Investments's 13F filing for Q4 2018, filed 14 Feb 2019.